Orchid Pharma Approves Allotment of 4.46 Crore Shares Under Dhanuka Laboratories Merger

Orchid Pharma has approved the allotment of 4,45,86,052 fully paid-up equity shares with a face value of ₹10 each as part of its merger with Dhanuka Laboratories Limited, as per an exchange filing dated August 1, 2026.  

The approval was granted at the board meeting held on August 1, 2026, following the merger becoming effective on July 10, 2026.  

Allotment to Eligible Shareholders 

The equity shares have been allotted to shareholders of Dhanuka Laboratories whose names appeared on the record date of July 23, 2026.  

Orchid Pharma noted that the shares will be listed on the NSE and BSE and will rank with the company's existing equity shares, carrying the same rights as those already in issue.  

Capital Structure Revised 

After the allotment and the cancellation of the cross-holding of Dhanuka Laboratories, Orchid Pharma's paid-up equity share capital has increased to ₹59.89 crore, comprising 5,98,85,200 equity shares of ₹10 each.  

The revised capital reflects the implementation of the approved merger scheme.  

Issuance Linked to Merger Scheme 

The company clarified that the shares have been issued only as part of the amalgamation and not through a preferential allotment, bonus issue or any other capital-raising exercise.  

In its exchange filing, Orchid Pharma stated that disclosure requirements relating to preferential issues, debt securities, depository receipts and bonus issues are not applicable to this transaction.  

Exchange Disclosure 

The filing was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, read with the applicable SEBI Master Circular.  

Orchid Pharma also referred to its earlier disclosures dated July 10 and July 28, 2026, which informed the exchanges about the merger taking effect and the scheduled board meeting.  

Read More: BEL Secures ₹847 Crore Worth of Fresh Orders; Share Price Closes Flat on July 31, 2026! 

Orchid Pharma Share Price Performance  

As of July 31, 2026, 3:30 pm, Orchid Pharma Ltd share price closed at ₹991.00, down 0.92% from the previous closing price. 

Conclusion 

The company's July sales were driven by growth in domestic dispatches, while cumulative sales for the first four months of FY2026-27 exceeded the year-ago period despite a marginal decline in monthly exports. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.